N-methyl-D-aspartate receptor-associated choline efflux pathway (NMDA-associated choline efflux)

The N-methyl-D-aspartate (NMDA) receptor-associated choline efflux pathway is a biochemical process rather than a single molecular target. It describes the phenomenon where activation of NMDA receptors leads to an increase in extracellular choline levels, primarily through the activation of calcium-dependent phospholipases that hydrolyze membrane phospholipids like phosphatidylcholine. This pathway is significant in neurobiology because it links excitatory glutamatergic signaling with the availability of choline, a precursor for the neurotransmitter acetylcholine. In neurodegenerative conditions such as Alzheimer's disease, overactivation of this pathway (excitotoxicity) can lead to the depletion of membrane phospholipids, contributing to cellular structural damage. While the pathway itself is not a drug target, the NMDA receptor that initiates this efflux is a major therapeutic target for drugs like memantine. Consequently, this pathway serves as a functional readout of NMDA receptor activity and membrane integrity in the central nervous system.

Other names

NMDA-evoked choline releaseGlutamate-stimulated choline effluxNMDA receptor-mediated phospholipase activation

Indirect modulation via NMDA receptor antagonism, which prevents the calcium-dependent activation of phospholipases (like PLA2 or PLD) that break down membrane phosphatidylcholine into free choline.